Diseases caused by the pneumococcus represent the largest cause of vaccine preventable death in the world today, mainly pneumonia and meningitis. In 2011, 16 developing countries will introduce pneumococcal conjugate vaccines, none in east Asia. Lack of research has been a major barrier to their use in the region. We have established an international centre of excellence in the field and we seek support to extend the capacity of this group and to transfer the technology to Vietnam.
Impact Of DTP Schedules On The Immunogenicity Of 2 Doses Of 13v-PCV Followed By An Early Booster
Funder
National Health and Medical Research Council
Funding Amount
$2,651,687.00
Summary
This project aims to come up with a vaccination schedule to make pneumococcal vaccines more effective and affordable for Fiji and other developing countries. We will evaluate schedules involving a 2 dose primary series in early infancy with a booster at 9 months of age. We will compare the immune responses to 3 different primary series and 2 booster options. The results of this project will be used to provide advice, at global and country levels, regarding introduction of pneumococcal vaccines.
Immunising Aboriginal Mothers With Pneumococcal Polysaccharide Vaccine To Prevent Infant Ear Disease And Carriage
Funder
National Health and Medical Research Council
Funding Amount
$1,131,530.00
Summary
Aboriginal children experience the highest rates of acute and chronic ear infections in the world, with resultant permanent ear damage, hearing loss and educational disadvantage. These infections are mainly bacterial, and Streptococcus pneumoniae (pneumococcus) is the predominant pathogen. Pneumococcal colonisation and infection begins within days of birth, many months before any potential immunological protection from infant pneumococcal conjugate vaccine may be expected. New strategies are nee ....Aboriginal children experience the highest rates of acute and chronic ear infections in the world, with resultant permanent ear damage, hearing loss and educational disadvantage. These infections are mainly bacterial, and Streptococcus pneumoniae (pneumococcus) is the predominant pathogen. Pneumococcal colonisation and infection begins within days of birth, many months before any potential immunological protection from infant pneumococcal conjugate vaccine may be expected. New strategies are needed to eliminate, or at least delay, this early-onset pneumococcal colonisation. One such strategy is the administration to the mother of pneumococcal vaccine, which may protect the newborn infant by leading to higher titres of transplacental or breast milk pneumococcal antibodies and-or by reducing carriage (and transmission to the infant) of maternal pneumococci. Previous small studies using this strategy have been encouraging, but there have been no studies properly evaluating carriage or disease endpoints in infants. The polysaccharide pneumococcal vaccine is currently recommended for all Aboriginal and Torres Islander persons aged 15 years or more in the Northern Territory but uptake of the vaccine has been poor. We propose to conduct a pilot study to determine if maternal immunisation with this vaccine, either in the third trimester of pregancy of immediately following delivery, can reduce pneumococcal carriage and the prevalence of middle ear disease among Aboriginal infants at seven months of age. We aim to recruit 210 Aboriginal women who have uncomplicated pregnancies from Darwin and remote communities in the Top End of the Northern Territory. Each subject and their infant offspring will be followed-up after vaccination and at birth, one , two and seven months after birth.Read moreRead less
A Study To Investigate Alternative Regimens For Pneumococcal Vaccination Of Infants In A Developing Country
Funder
National Health and Medical Research Council
Funding Amount
$1,622,210.00
Summary
Streptococcus pneumoniae (Pnc) is the leading vaccine preventable cause of serious infection in infants. The current Pnc conjugate vaccine is very expensive (approximately USD $200-infant) so it is unlikely to be affordable for most developing countries. Moreover, as health care access in developing countries may be episodic and unreliable, many children do not receive either complete or timely vaccine courses. Therefore, it is important to investigate affordable and flexible ways to deliver thi ....Streptococcus pneumoniae (Pnc) is the leading vaccine preventable cause of serious infection in infants. The current Pnc conjugate vaccine is very expensive (approximately USD $200-infant) so it is unlikely to be affordable for most developing countries. Moreover, as health care access in developing countries may be episodic and unreliable, many children do not receive either complete or timely vaccine courses. Therefore, it is important to investigate affordable and flexible ways to deliver this vaccine, which are safe and effective. A recent WHO-GAVI meeting to address impediments to the introduction of these vaccines in developing countries recognized the need to evaluate other regimens of Pnc conjugate vaccine as an important research priority. This study has been deliberately formulated with that need in mind. The site for this research is Fiji. Although health services are good, Pnc disease, particularly pneumonia, remains the commonest cause of childhood morbidity and mortality. Fiji has good vaccine coverage and was the first Pacific country to introduce Hib vaccine. The arrival of the new, expensive Pnc conjugate vaccine presents a dilemma for Fiji and many similar countries. The expense of this vaccine would consume a large portion of the health budget. This study has two components: 1. A Phase 2 immunogenicity study (involving 750 infants) to evaluate regimens using reduced numbers of doses of Pnc conjugate vaccine, and using timing of dosing and combinations with the Pnc polysaccharide (PS) vaccine that may be more suited to the epidemiology of Pnc disease in developing countries. 2. An epidemiological study will measure the burden of invasive Pnc disease and pneumonia in Fiji. This will be part of a global effort to address these issues, and will be used to develop rapid assessment tools for these diseases in developing countries. We will seek cofounding for this component.Read moreRead less
Mathematical Modelling For Improved Planning Of Infectious Diseases Control Policy
Funder
National Health and Medical Research Council
Funding Amount
$2,750,000.00
Summary
We will develop high-level technical capacity in mathematical modeling of infectious disease transmission and control in Australia, with a focus on research that informs health policy. The aim is to assist Australia to have efficient and effective control strategies and help to prepare us against the threat of emerging infections. Priority areas are vaccination programs, HIV-AIDS, emerging infections and bio-terrorism. Six talented young researchers will be trained by the lead applicant team. To ....We will develop high-level technical capacity in mathematical modeling of infectious disease transmission and control in Australia, with a focus on research that informs health policy. The aim is to assist Australia to have efficient and effective control strategies and help to prepare us against the threat of emerging infections. Priority areas are vaccination programs, HIV-AIDS, emerging infections and bio-terrorism. Six talented young researchers will be trained by the lead applicant team. Together, we will develop a prominent and experienced research team capable of sustaining international quality research into the future. Their work will meet immediate, existing policy needs at state, national and global levels. The program includes the establishment of a Network of Infectious Diseases Modellers of Australia (NIDMA) as a research resource of national expertise, peer support and a means of ongoing communication and collaboration in infectious diseases control. The critical mass of modeling expertise that we create will be sustainable long-term, and will expand to support research concerned with chronic and other non-infectious diseases after the lifetime of the grant.Read moreRead less
Reducing antibiotic usage in pig herds: controlling Lawsonia intracellularis by vaccination, housing and hygiene. Pigs are major consumers of antibiotics in Australia. Many of these antibiotics are fed to pigs to prevent proliferative enteritis (PE). There are increasing public concerns regarding the development and spread of antibiotic-resistant bacteria and the potential impact on human health. The adoption of an effective commercial vaccine to prevent PE will reduce the volume of antibiotics ....Reducing antibiotic usage in pig herds: controlling Lawsonia intracellularis by vaccination, housing and hygiene. Pigs are major consumers of antibiotics in Australia. Many of these antibiotics are fed to pigs to prevent proliferative enteritis (PE). There are increasing public concerns regarding the development and spread of antibiotic-resistant bacteria and the potential impact on human health. The adoption of an effective commercial vaccine to prevent PE will reduce the volume of antibiotics used in the pig industry and hence reduce the risk of antibiotic-resistant bacteria developing.Read moreRead less
Development of an anti-Chlamydia vaccine for the koala. The koala is one of Australia's main icons and a major drawcard for tourists. However, it suffers from debilitating disease due to the bacterium Chlamydia, which can lead to severe conjunctivitis, eventual blindness in both sexes, and the females develop untreatable cysts and can become infertile. This project will develop a Chlamydia vaccine to be administered to healthy and diseased koalas in zoos, sanctuaries, koala care centres, relocat ....Development of an anti-Chlamydia vaccine for the koala. The koala is one of Australia's main icons and a major drawcard for tourists. However, it suffers from debilitating disease due to the bacterium Chlamydia, which can lead to severe conjunctivitis, eventual blindness in both sexes, and the females develop untreatable cysts and can become infertile. This project will develop a Chlamydia vaccine to be administered to healthy and diseased koalas in zoos, sanctuaries, koala care centres, relocation programs and eventually perhaps even wild populations. The vaccine findings may also be transferable to other animals and may also even assist the development of a human Chlamydia vaccine.Read moreRead less
Oxide Bioceramics for Drug Delivery. Australia has the highest rate of skin cancer in the world. One out of every two Australians will develop skin cancer at some stage during their lives. On average, 740,000 new cases of skin cancer are diagnosed in Australia every year (1 million in the USA). The cost to Australia is over $200 million/year. While today more people are aware of the dangers of UV, the desire to be fashionable outweighs their health concerns. Melanotan is a novel sunscreen soluti ....Oxide Bioceramics for Drug Delivery. Australia has the highest rate of skin cancer in the world. One out of every two Australians will develop skin cancer at some stage during their lives. On average, 740,000 new cases of skin cancer are diagnosed in Australia every year (1 million in the USA). The cost to Australia is over $200 million/year. While today more people are aware of the dangers of UV, the desire to be fashionable outweighs their health concerns. Melanotan is a novel sunscreen solution: a drug that stimulates the body's natural defence mechanism against UV light. Alumina and zirconia bioceramics are ideal implantable drug delivery vehicles because of the long leaching periods possible.Read moreRead less
Molecular and antibody analysis of cytomegalovirus (CMV) infection of fetal and placental cells. CMV is a beta herpesvirus with many unknown molecular mechanisms associated with cellular infection. The virus infects placental cells in vivo, although pathogenesis of viral damage to these cells has been extremely difficult to study in vitro. We have commenced a study to i) demonstrate the molecular accompaniments of infection of placental cells in vitro, ii) determine the genotypic characteristics ....Molecular and antibody analysis of cytomegalovirus (CMV) infection of fetal and placental cells. CMV is a beta herpesvirus with many unknown molecular mechanisms associated with cellular infection. The virus infects placental cells in vivo, although pathogenesis of viral damage to these cells has been extremely difficult to study in vitro. We have commenced a study to i) demonstrate the molecular accompaniments of infection of placental cells in vitro, ii) determine the genotypic characteristics of congenital CMV infections, in collaboration with Abbott Diagnostics, and iii) produce an in vivo model of CMV infection to demonstrate the pathogenesis of cellular injury. The combination of molecular expertise at UNSW with monoclonal antibody expertise from Abbott Diagnostics mean this project is unique worldwide.Read moreRead less